Vistagen Therapeutics (VTGN) EPS (Basic) Growth (3y) (2015 - 2026)
Vistagen Therapeutics (VTGN) EPS (Basic) Growth (3y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.52 Bn | 132.67 Bn | 2.84 Bn | 6.85% |
| 2 | Regeneron Pharmaceuticals | 86.54 Bn | 78.55 Bn | 3.93 Bn | 11.71% |
| 3 | Argenx Se | 65.31 Bn | 60.13 Bn | 1.37 Bn | 64.84% |
| 4 | Moderna | 61.77 Bn | 56.64 Bn | 52.00 Mn | 18.44% |
| 5 | BeOne Medicines | 42.26 Bn | 37.16 Bn | 1.53 Bn | 37.21% |
| 6 | Alnylam Pharmaceuticals | 31.19 Bn | 27.88 Bn | 992.69 Mn | 36.73% |
| 7 | BioNTech SE | 28.71 Bn | 10.31 Bn | 668.28 Mn | -26.87% |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 67.51% |
| 9 | Royalty Pharma | 27.35 Bn | 26.52 Bn | - | -38.31% |
| 10 | Vistagen Therapeutics | 10.41 Mn | 10.41 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 37.55% |
| Dec 31, 2025 | 31.88% |
| Sep 30, 2025 | 40.17% |
| Jun 30, 2025 | 45.20% |
| Mar 31, 2025 | 44.12% |
| Dec 31, 2024 | 33.96% |
| Sep 30, 2024 | 40.85% |
| Jun 30, 2024 | 35.06% |
| Mar 31, 2024 | 63.71% |
| Dec 31, 2023 | 53.08% |
| Sep 30, 2023 | 26.17% |
| Jun 30, 2023 | 22.68% |
| Mar 31, 2023 | 10.58% |
| Dec 31, 2022 | 31.30% |
| Sep 30, 2022 | 13.92% |
| Jun 30, 2022 | 14.43% |
| Mar 31, 2022 | 26.30% |
| Dec 31, 2021 | 39.90% |
| Sep 30, 2021 | 38.91% |
| Jun 30, 2021 | 39.76% |